Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-08-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于2018年股票期权激励计划预留授予股票期权第一个行权期行权条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding the achievement of conditions for the first exercise period of reserved stock options under its 2018 stock option incentive plan. It includes extensive information about the stock option plan, approval procedures, performance conditions, exercise arrangements, and legal opinions. The document is not a financial report like an annual or interim report, nor is it a simple announcement of voting results or a proxy statement. It is a regulatory announcement about stock option exercise conditions and related corporate governance matters. It also includes information about insider share transactions related to the stock options. Given the nature of the content, which focuses on stock option incentive plan details, exercise conditions, and related approvals, this fits best under the category of Regulatory Filings (RNS), as it does not match other more specific categories like Director's Dealing (DIRS) because it is not solely about insider trades, nor is it a remuneration report (DEF 14A). The document is comprehensive and over 12,000 characters, so it is not a mere report publication announcement (RPA). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-16 Chinese
北京国枫律师事务所关于公司2018年股票期权激励计划之注销部分股票期权与首次授予股票期权第二个行权期及预留授予股票期权第一个行权期行权条件成就的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 stock option incentive plan of Yunnan Watson Biotechnology Co., Ltd. It details the cancellation of some stock options and the achievement of exercise conditions for certain stock option exercise periods. The document references relevant laws and regulations, approval and decision-making procedures by the company's board and supervisory board, and confirms compliance with regulatory requirements. It is a legal opinion related to stock option incentive plans, not a financial report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. The document is lengthy (9887 characters) and contains detailed legal analysis and confirmation of compliance, which fits the category of a Regulatory Filing (RNS) as it is a legal opinion and compliance document rather than a financial report or announcement of a report. Therefore, the best classification is Regulatory Filings (RNS).
2021-08-16 Chinese
关于对全资子公司增资并完成工商变更登记的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the company's capital increase in its wholly-owned subsidiary and the completion of the related business registration changes. It details the increase in registered capital and confirms the company's continued 100% ownership. There is no financial report, earnings data, or management discussion. The document is a formal announcement of a capital change event, specifically an increase in capital of a subsidiary and registration update. This fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2021-08-12 Chinese
独立董事关于第四届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion regarding a board meeting decision about a subsidiary's loan application. It references regulatory guidelines and company bylaws but does not contain financial statements or detailed financial data. The content is related to board/management oversight and approval of financing activities but is not a direct financing update or capital change announcement. It is a formal opinion from independent directors on a board matter, which fits best under Board/Management Information (MANG). The document length is short and focused on management-level decision commentary rather than a full report or announcement.
2021-07-28 Chinese
第四届监事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 4th Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related announcements on a regulatory disclosure website. The content focuses on supervisory board decisions, including approval of a rectification report and loan applications by a subsidiary. There are no financial statements, earnings data, or detailed management analysis present. The document is not a full report but an official announcement of board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2021-07-28 Chinese
第四届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Yunnan Watson Biotechnology Co., Ltd. It details the convening of the fourth board's 25th meeting, the approval of a rectification report in response to regulatory measures, and approval of loan applications by a subsidiary. The document includes voting results and references to related disclosures on an official information disclosure website. There is no financial data or detailed report content, only the announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2021-07-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.